Immuno-Oncology Reports






Immuno-oncology also is known as cancer immunotherapy, describes the process of utilizing the patient's immune system to fight cancer. Immuno-oncology is the cancer treatment with therapies that stimulate or suppress the body's immune system. In the last ten years, immuno-oncology has come up as an exciting approach to cancer treatment due to its specificity, adaptability and durability. One of the main areas within this field is a new class of proteins called immune checkpoints, such as PD-1, which could enable cancer cells to hide from the immune system by modulating T cell signalling. 

Several distinct modalities of Immuno-oncology therapy exist, including bispecific T-cell engaging monoclonal antibodies, cellular immunotherapy and adoptive cellular therapy, cancer vaccines, checkpoint modulating monoclonal antibodies, and oncolytic viruses. 

The immuno-oncology market is expected to reach USD 6 billion by 2024 from USD 3 billion in 2018, at a CAGR of 12% during the forecast period. The growth of this immuno-oncology market is primarily driven by factors such as the increasing adoption of targeted therapy over traditional therapy and increasing demand for monoclonal Antibodies. 

There is a slew of companies like DelveInsight and many others that prepare immuno-oncology reports.  
DelveInsight’s report- "Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges, 2019", emphasizes on the currently active CAR-T cell products in research and development. The immuno-oncology report provides an in-depth analysis of key market trends and governing factors along with market attractiveness as per segments. The immuno-oncology report also provides the qualitative impact of various market factors on various CAR-T market segments and geographies. The comprehensive insights provided in the immuno-oncology report will help the companies in identifying better opportunities. 

The immuno-oncology report covers the 100+ companies with 270+ CAR-T therapies, which are active in this field, including 50+ clinical companies with 90+ products targeting more than 80+ different antigens and more than 20+ different technologies. 

The immuno-oncology report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, Collaborations details and Deal values, Technologies and Targeted antigens, Investments and fundings etc. The immuno-oncology report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by cost-analysis and SWOT Analysis. The report also covers the KOL views on CAR-T Therapy. Additionally, the report covers the comparative analysis of the sales of two approved drugs (Kymriah and Yescarta). The report also describes the unmet needs covered by CAR-T cells highlighting the adverse events, which are significant concerns in the market for the usage of CAR-T cells. The strategists can gain detailed insight and devise appropriate strategies to target a specific market. 




Comments

  1. UnknownFebruary 29, 2020 at 7:19 PM

    Did you know there's a 12 word sentence you can tell your crush... that will trigger intense emotions of love and instinctual attractiveness for you buried within his chest?

    That's because hidden in these 12 words is a "secret signal" that triggers a man's instinct to love, please and care for you with all his heart...

    ====> 12 Words Will Fuel A Man's Desire Impulse

    This instinct is so hardwired into a man's brain that it will drive him to work better than before to make your relationship the best part of both of your lives.

    Matter of fact, fueling this mighty instinct is so mandatory to having the best ever relationship with your man that once you send your man a "Secret Signal"...

    ...You will soon find him open his mind and soul for you in such a way he haven't expressed before and he will perceive you as the only woman in the universe who has ever truly attracted him.

    ReplyDelete

Post a Comment

Popular posts from this blog

Cyclin-dependent kinase

Image
Cyclin-dependent kinase overview Cyclin-dependent kinases (CDKs) belong to a protein serine/threonine kinases whose activity depends on association with a noncatalytic regulatory subunit called a cyclin. Cyclin-dependent kinases inhibitors are vital for progression through the cell cycle and proliferation. The genes that encode CDKs were initially identified in screens for conditional mutants of Saccharomyces cerevisiae which reversibly arrested at characteristic points in the cell cycle upon transfer to the restrictive conditions. Cyclins were initially named for their periodic accumulation and degradation (cycling) through the early cell cycles of fertilized sea urchin eggs. This research identified a ubiquitous cell cycle engine responsible for coordinating cell growth, DNA replication, and mitosis in the orderly fashion required to ensure the viability of progeny cells. How Do Cyclin-dependent kinases regulate Cell Cycle? All eukaryotes have a various cyclins,
Read more

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Smoking Cessation Market Research Report 2030 | Smoking Cessation Market

Image
Smoking Cessation   is a process of discontinuing tobacco smoking. Cigarette smoking is the leading cause of chronic obstructive pulmonary disease, and quitting smoking is the most effective way to slow down the progression of the disease. Tobacco use can potentially lead to tobacco or nicotine addiction, as well as significant health consequences, according to the CDC. It has the potential to significantly lower the risk of smoking-related diseases. Nicotine is addictive, but no effective medications or behavioral therapies are available to help people overcome it. Counseling, nicotine replacement, and bupropion have all been shown to aid in smoking cessation in several studies. Smoking Cessation Sign and Symptoms The most significant barrier to quitting smoking is nicotine addiction. Smokers who try to stop often experience cravings for cigarettes, mood swings, insomnia, constipation, increased hunger, anxiety, and other nicotine withdrawal symptoms. Tobacco quitting lowers the chanc
Read more